EvidentIQ, based in Hamburg, is a leading clinical data science group, offering an end-to-end platform of state-of-the art eClinical solutions (eConsent, EDC, CTMS, eCOA,) that helps its customers with the planning and execution of both hybrid/decentralized and traditional clinical trials. Thanks to its global patient platform Carenity, the group combines their technology with a direct access to real-world patient insights, enabling them to support sponsors and CROs with innovative offerings such as eFeasibility, eRecruitment and Real-World Evidence data collection and analysis
Dacima, based in Montreal, offers a cutting edge flexible Electronic Data Capture (EDC) platform for the design and management of clinical trials, observational studies, patient registries, clinical databases, electronic Patient Reported Outcomes (ePRO), eDiaries and eConsent. It’s advanced eClinical capabilities will enrich EvidentIQ Group product lineup with software solutions for electronic Clinical Outcome Assessment (eCOA) and eConsent. The company has been founded by experts in epidemiology, medical research and information technology who understand the needs of users and requirements of eClinical software for the healthcare sector.
By integrating EvidentIQ’s patient community, data science solutions and eClinical backbone with Dacima’s products, the group will provide the technology for hybrid and decentralized clinical trials (DCT) as a one-stop-shop on a global basis. This acquisition will help EvidentIQ to build a complete offer that covers every step in the value chain of clinical research and development, enhance their unique end-to-end solutions to help the life sciences industry run innovative patient-centric clinical studies and optimize clinical research.
EvidentIQ is a next generation technology-amplified data science group championing new standards in value creation and innovation driven relevance for customers. The EvidentIQ offering brings a pioneering end-to-end eClinical solution that meets increasing customer demand across clinical operations and clinical data management needs, with a suite of applications within a single integrated cloud platform. By combining its platform with a broad data science service portfolio including patient recruitment, patient engagement media and RWE solutions, EvidentIQ significantly aids customers in optimizing HTA submissions, pricing and reimbursement needs. EvidentIQ has become a pillar of Real-World Evidence and data science pioneering in digitalization of clinical research and offering state-of-the art eClinical solutions (eConsent, EDC, CTMS, eCOA).
EvidentIQ supports 15 of the top 20 pharma companies through novel RWE solutions and 150+ SMB customers in over 20 countries, including the US, Germany, France, the UK, Italy, Japan and China.
EvidentIQ Group GmbH
Rathausmarkt 5
20095 Hamburg
Telefon: +49 (89) 4522775000
Telefax: +49 (89) 4522775900
https://evidentiq.com
CEO
E-Mail: andreas.weber@evidentiq.com
